文献速递脑血管病

不明来源栓塞性卒中后双联抗血小板治疗:CHANCE-2试验的亚组分析

Dual Antiplatelet Therapy After Embolic Stroke of Undetermined Source: A Subgroup Analysis of the CHANCE-2 Trial.
PubMed 文献 · Stroke · 2024-06-11

该研究为CHANCE-2试验的预设探索性亚组分析,纳入5796例携带CYP2C19功能缺失等位基因的轻型卒中或短暂性脑缺血发作患者,其中881例(15.2%)为不明来源栓塞性卒中(ESUS)。在ESUS患者中,替格瑞洛联合阿司匹林组90天卒中复发率为5.6%,氯吡格雷联合阿司匹林组为9.2%(HR 0.57,95%CI 0.33-0.99,P=0.04)。

要点

  • ESUS患者中替格瑞洛联合阿司匹林较氯吡格雷联合阿司匹林降低90天卒中复发风险(HR 0.57)。
  • 非ESUS患者中相应复发率为5.6% vs 7.5%(HR 0.72,95%CI 0.58-0.90,P<0.01)。
  • 治疗与ESUS状态的交互作用P=0.56。

核心结论

  • 在携带CYP2C19功能缺失等位基因且被归类为ESUS的急性缺血性卒中或短暂性脑缺血发作患者中,替格瑞洛联合阿司匹林在预防90天卒中方面优于氯吡格雷联合阿司匹林。

研究设计与样本

  • CHANCE-2为研究者发起的多中心、随机、双盲、安慰剂对照试验,在中国比较替格瑞洛联合阿司匹林与氯吡格雷联合阿司匹林用于携带CYP2C19功能缺失等位基因的轻型卒中或短暂性脑缺血发作患者。
  • 本分析为预设探索性亚组分析,将参与者分为ESUS与非ESUS组,共纳入5796例(占CHANCE-2试验总6412例的90.4%),中位年龄64.9岁(范围57.0-71.4岁),女性1964例(33.9%)。

主要发现

  • 经系统评估,881/5796例(15.2%)患者被判定为ESUS。
  • ESUS患者中,替格瑞洛联合阿司匹林组卒中复发率为5.6%,氯吡格雷联合阿司匹林组为9.2%(HR 0.57,95%CI 0.33-0.99,P=0.04)。
  • 非ESUS患者中,替格瑞洛联合阿司匹林组卒中复发率为5.6%,氯吡格雷联合阿司匹林组为7.5%(HR 0.72,95%CI 0.58-0.90,P<0.01)。
  • 治疗与ESUS状态的交互作用P=0.56。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The atherosclerotic sources of embolism are a significant contributor to embolic stroke of undetermined source (ESUS). However, there is limited evidence for the efficacy of intensive dual antiplatelet therapy for ESUS. We conducted an investigation to determine whether gene-directed dual antiplatelet therapy could reduce the risk of recurrent stroke in patients with ESUS. METHODS: CHANCE-2 (Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events-II) was an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial that objectively compared ticagrelor plus aspirin and clopidogrel plus aspirin in patients with minor stroke or transient ischemic attack who carried CYP2C19 loss-of-function alleles in China. All study participants were classified into ESUS and non-ESUS groups for the prespecified exploratory analysis. Cox proportional hazards models were used to assess the interaction of the state of ESUS with the effects of dual antiplatelet therapy with ticagrelor-aspirin versus clopidogrel-aspirin, adjusting for sociodemographic and clinical factors. RESULTS: The subgroup analysis comprised 5796 participants (90.4% of the total 6412 participants) in the CHANCE-2 trial, with a median age of 64.9 years (range, 57.0-71.4 years), of whom 1964 (33.9%) were female. These participants underwent diffusion-weighted imaging as part of the study protocol. After systematic evaluation, 15.2% of patients (881/5796) were deemed to have ESUS. The incidence of stroke recurrence in patients with ESUS was found to be 5.6% in the ticagrelor-aspirin group and 9.2% in the clopidogrel-aspirin group (hazard ratio, 0.57 [95% CI, 0.33-0.99]; P=0.04). In patients without ESUS, the respective incidence rates were 5.6% and 7.5% (hazard ratio, 0.72 [95% CI, 0.58-0.90]; P<0.01). The P value was 0.56 for the treatment × ESUS status interaction effect. CONCLUSIONS: In this prespecified exploratory analysis, ticagrelor with aspirin was superior to clopidogrel with aspirin for preventing stroke at 90 days in patients with acute ischemic stroke or transient ischemic attack who carried CYP2C19 loss-of-function alleles and were classified as ESUS. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04078737.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Xie X, Jing J, Meng X, et al. Dual Antiplatelet Therapy After Embolic Stroke of Undetermined Source: A Subgroup Analysis of the CHANCE-2 Trial. Stroke. 2024. PMID: 38860396. doi:10.1161/STROKEAHA.124.046834

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。